drugset
drugset / Trial / NCT04214626

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

NCT04214626 ↗

Phase 2 Completed 60 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single-arm, multi-center, phase II clinical trial to observe the efficacy and safety of R-CHOP (Rituximab-Cyclophosphamide, Epirubicin, Vincristine and Prednisone) combined with lenalidomide in the first-line treatment for patients with medium to high risk/high risk diffuse large B cell lymphoma.

Timeline

Start
2020-01-05
Primary completion
2023-12-31
Completion
2025-04-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Epirubicin Small molecule 70 mg/m2 Intravenous
Background Methotrexate Small molecule 1 g Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Background Vincristine Small molecule 1.4 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma